Tandem Diabetes Care, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Tandem Diabetes Care, Inc. (TNDM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2023-02-22
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2022-06-30 was $0.00.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2021 was $15.50M, a 41.14% decline from fiscal 2020.
- Tandem Diabetes Care, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2020 was $26.34M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $0.00 derived: sum of 3 quarters · filed 2023-02-22 | $0.00 10-K · filed 2023-02-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $0.00 10-Q · filed 2022-11-02 | $1.00K derived: sum of 4 quarters · filed 2023-02-22 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $0.00 10-Q · filed 2022-08-03 | $1.00K derived: sum of 3 quarters · filed 2023-02-22 | $3.07M derived: sum of 4 quarters · filed 2023-02-22 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | $1.00K derived: sum of 2 quarters · filed 2023-02-22 | $3.07M derived: sum of 3 quarters · filed 2023-02-22 | $3.07M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $3.07M derived: sum of 2 quarters · filed 2023-02-22 | $3.07M derived: sum of 3 quarters · filed 2023-02-22 | $15.50M 10-K · filed 2023-02-22 |
| 2021-09-30 | $3.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $3.06M derived: sum of 2 quarters · filed 2022-11-02 | $15.50M 10-Q · filed 2022-11-02 | $15.82M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $12.43M 10-Q · filed 2022-08-03 | $12.76M derived: sum of 3 quarters · filed 2023-02-22 | $38.63M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $12.43M 10-Q · filed 2022-05-04 | $12.76M derived: sum of 2 quarters · filed 2023-02-22 | $38.63M derived: sum of 3 quarters · filed 2023-02-22 | |
| 2020-12-31 | $324.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $26.19M derived: sum of 2 quarters · filed 2023-02-22 | $26.34M 10-K · filed 2023-02-22 | |
| 2020-09-30 | $25.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $26.01M 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $142.00K 10-Q · filed 2021-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |